NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ANDRODERM (testosterone) by AbbVie is androgen receptor agonists [moa]. Approved for hypogonadism, testosterone deficiency. First approved in 1995.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANDRODERM is a transdermal testosterone replacement therapy indicated for hypogonadism, testosterone deficiency, and related conditions including sexual dysfunction, sarcopenia, and bone loss. It works as an androgen receptor agonist, delivering testosterone through extended-release film for systemic absorption. The product targets male patients with clinically low testosterone across multiple therapeutic contexts.
$3MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Medicare spending suggests a mature brand in transition; commercial teams should expect resource reallocation and preparation for generic competition.
Mechanism of Action
Androgen Receptor Agonists
Indications (2)
Clinical Trials (20)
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Started Jun 2026
20 enrolled
Multiple SclerosisErectile DysfunctionTestosterone Deficiency
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Started Mar 2026
60 enrolled
Metastatic Castration-resistant Prostate Cancer
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
Started Jul 2025
48 enrolled
Spinal Cord InjuriesEndothelial DysfunctionTestosterone Deficiency
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Started Mar 2025
100 enrolled
Hypogonadism, Male
Puberty, Testosterone, and Brain Development
Started Dec 2024
100 enrolled
Gender IdentityGender Dysphoria in Adolescents and AdultsHeadache+1 more
Worked on ANDRODERM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.